Introduction
The vocal folds are a remarkably unique tissue in the body, in that they can produce vibration at rates between 100-1000 hertz throughout the course of a day (Guimaraes & Abberton, 2005; Hunter et al., 2006) . When this robust tissue is disrupted by scarring associated with vocal fold lesion excision, carcinoma, radiation, trauma, or inflammatory disease, the associated degradation in vocal quality can be devastating. More than half of individuals with voice disorders attribute their dysphonia as having a negative impact on their social interactions, career and mental health (Smith et al., 1995) . Traditional surgical treatments and voice therapy have been suboptimal for improving the dysphonia and fatigue associated with vocal fold scarring (Hansen & Thibeault, 2006) . Over the past decade, a number of promising pre-clinical studies targeted at vocal fold regeneration using mesenchymal stem cells (MSCs) have been completed. As nearly all of the dedicated stem cell investigation has been completed in vitro and in animal models, there exists a great opportunity for innovation and landmark work in the future of this field. Our intention is to present the therapeutic interventions explored in the literature to date for mesenchymal stem cell (MSC) based approaches for vocal fold regeneration, in order to inform optimal approaches of the future. 
Therapeutic interventions explored to date

Cells
MSCs have many favorable characteristics, including an ability to migrate to a site of injury and to encourage proliferation and differentiation of progenitor cells. They have also been shown to exert control over the microenvironment via secretion of growth factors and matrix remodeling (Caplan, 2007; Uccelli et al., 2007) . There is evidence that the activity of T-lymphocytes, B-lymphocytes, and natural killer cells can be inhibited by MSCs, which suggests their potential allogeneic use without risk of immune response (Le Blanc & Ringden, 2007; Rasmussen et al., 2007) . Interestingly, bone marrow derived mesenchymal stem cells (BM MSCs), adipose derived mesenchymal stem cells (ASCs) and human vocal fold fibroblasts found in the lamina propria demonstrate similar immunophenotypic properties, differentiation potential and cell surface markers (Long et al., 2009; Puissant et al., 2005; Hanson et al., 2010) . This shared cell surface profile included a positive expression for MSC markers (i.e., CD29, CD44, CD73, CD90 and CD105) and a negative expression for hematopoietic stem cell markers (i.e., CD14, CD31, CD34, CD45). Additionally, BM MSCs and ASCs have been shown to differentiate down epithelial and fibroblast lineages (Kanemaru et al., 2005; Long et al., 2009; Ohno et al., 2009 ). Collectively, these findings support the use of BM MSCs and ASCs in future vocal fold regeneration interventions.
Further inquiry distinguishing the utility of these two cell sources is necessary, as there have been no in vivo reports directly comparing them in laryngeal research.
There have been a few reports of injecting MSCs directly into the vocal fold, without a scaffold or soluble factors, in order to encourage regeneration following injury (see Table 1 ). These in vivo animal models have generally used a common investigative paradigm, which involves first creating a lesion unilaterally or bilaterally in the membranous portion of the vocal fold. After a period of days to weeks which allows the mature scar to form, the investigator then injects the cell therapy into the scarred region. Outcomes are determined with morphological assessment to characterize the anatomical structure of the tissue, rheometric analysis to determine the tissue's viscoelasticity, and/or with gene or protein expression levels to analyze extracellular matrix component production. Measures of tissue biomechanics may be the most meaningful outcome to report in vocal fold literature, as viscoelasticity is known to significantly affect voice quality and patient outcomes. Thus, rheometric assessment is becoming an important functional measure in laryngeal literature. Improved viscoelastic measures have been reported for vocal folds treated with BM MSCs alone in a rabbit model (Hertegård et al., 2006a; Svensson et al., 2010) . Improved tissue morphology (less granulation tissue, less rough vocal fold edge) has been reported in injured vocal folds treated with BM MSCs as compared with controls, over a recovery periods lasting from four and twelve weeks (Hertegård et al., 2006a; Kanemaru et al., 2005 , Svensson et al., 2010 . Figure 1 demonstrates the resolution of one dog's granuloma and rough vocal fold morphology over a 24 week recovery period. Protein and gene expression analysis can provide useful information about signaling pathways and ECM production. The literature to date has focused largely on the expression and some quantification of the ECM components known to be involved with wound healing, such as collagen, fibronectin, and hyaluronic acid. A reduction in collagen I content (Hertegård et al., 2006a , Svensson et al., 2010 and an increase in TGF-β1 production have been reported in vocal folds injected with BM MSCs alone versus scarred, untreated controls. Additionally, it has been found in vitro that a coculture of ASCs and scar fibroblasts (SF) had decreased collagen production levels and www.intechopen.com
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SF proliferation rates when compared with SFs in monoculture (Kumai et al., 2009) . These data suggest that BM MSCs and ASCs support an anti-fibrotic profile when exposed to a scar environment. Further protein and gene expression investigation is needed to uncover signaling pathways that may allow future bioengineers to control these processes. An optimal cell source to remediate vocal fold scarring and promote regeneration would be non-immunogenic, remain viable amidst significant vibration, migrate to the site of injury, encourage remodeling of ECM to reduce the fibrotic scar profile and efficiently differentiate into vocal fold fibroblasts and epithelial cells. To date, a handful of initial studies have indicated the therapeutic potential of injecting BM MSCs or ASCs alone for vocal fold regeneration, but further characterization using the above criteria may prove useful. Investigation using pluripotent cells (embryonic stem cells, induced pluripotent stem cells) and MSCs isolated from other sources (i.e., spleen, thymus, umbilical cord blood, amniotic fluid and dental pulp) may also be considered.
Scaffolds without cells
Scaffold materials have long been used in injection laryngoplasty procedures by otolaryngologists for the treatment of patients with vocal fold paresis, paralysis or anatomical defects. In this treatment, the biomaterial/scaffold is primarily used as a bulking agent to push the affected vocal fold toward midline and allow for a closer physical approximation during phonation. Synthetic materials (silicone, polytetrafluoroethylene-Teflon, polyhydroxyethylmethacrylate) have largely been eschewed for clinical use because of their propensity for foreign body response, migration of material and non-biodegradability (Ejnell et al., 1984; Nakayama et al., 1993) . These materials have been replaced in the clinic by more degradable biomaterials, such as collagen matrix (Kriesel et al., 2002) and fat (McCulloch et al., 2002; Lo Cicero et al., 2008) . These materials have viscoelastic properties more similar to vocal mucosa than the previous injectables. Additionally, the site of injection has changed from the thyroartenoid muscle to the lamina propria. Interestingly, it has recently reported that abdominal adipose tissue harvested for clinical use as a fat injection contains a local population of MSCs. These stem cells have a high proliferative potential and the ability to differentiate down multiple lineages (Lo Cicero et al., 2008) . These data suggest that a resident MSC population in vocal fold fat injections may contribute to long-term graft survival, which is suspected to occur in 55-100% of patients (McCulloch et al., 2002; Lo Cicero et al., 2008) . Commercially available composite materials have also been commonly used in clinic, such as Gelfoam paste (Schramm et al., 1978) , Cymetra (Milstein et al., 2005) , calcium hydroxylapatite (Rosen et al., 2007) , Restylane and Hylaform (Hertegard et al., 2006b) . While these materials have all been reported to improve vocal function, they are not traditionally thought to grow and remodel the tissue, as many of them biodegrade in the body. Resorption is an advantage for patients with temporary vocal fold pathology and for those interested in a short-term trial, but it is a significant limitation for patients that are interested in long-term treatment, as they can necessitate repeated injections. A promising line of research is the investigation of gels and hydrogels as vocal fold injectables, as they may offer greater potential for vocal fold regeneration and improved viscoelastic properties over current scaffold materials. To date, hydrogels have primarily been HA based (Duflo et al., 2006a , Duflo et al., 2006b , Jia et al., 2004 and collagen based (Hahn et al., 2006) . Figure 2 demonstrates the distinct rheometric measurements obtained from four treatment groups that included a semi-synthetic gel matrix (Thibeault et al., 2009) . Decellularized xenogeneic matrices derived from porcine small intestine, urinary bladder and bovine vocal fold tissue have also been investigated as potential laryngeal scaffolds (Ringel et al., 2006; Xu et al., 2007) . In this model, the tissue is decellularized, leaving the potential for ECM-based repair of native via release of endogenous growth factors and activation of local cells.
Scaffolds with cells
There are many well characterized biomaterials used for injection laryngoplasty, though, only a few substances (i.e., HA based hydrogels, atelocollagen, fibrin) have been investigated for use as scaffolds in vocal fold MSC based therapies (Long et al., 2009; Kanemaru et al., 2003; Lee et al., 2010; Quinchia-Johnson et al., 2010; Ohno et al., 2009 ). HA based hydrogels have been shown to be noninflammatory, nonimmunogenic and biocompatible, as well as have significant shock absorption ability. Carbylan-GSX (a thinlymodified semisynthetic GAG derived of HA mixed with a thiolated gelatin, and cross linked with polyethylene glycol), has viscoelastic properties similar to vocal mucosa when injected in vivo (Duflo et al., 2006a) . When encapsulated in Extracel, BM MSCs maintained a high viability (96% or better), and were able to sustain their cell growth over a three day period (Duflo et al., 2006b ). They remained alive 30 days post injection (See Fig. 3 ). In addition, this construct injected in vivo produced an ECM profile more supportive of wound healing (i.e., increased expression of fibronectin and pro-collagen III) than a cells only approach and the control condition . Atelocollagen, a biomaterial found in a few recent reports, is derived from calf dermis and can be degraded in vivo by endogenous collagenase at a slower rate than collagen scaffolds. It can be used for tissue engineering purposes in an unmodified form , made into a sponge (Ohno et al., 2009) or into a gel (Kanemaru et al., 2003) . Adherence of cells to the material is an important criterion for potential scaffold biomaterials. Approximately 20% of BM MSCs initially adhered to an atelocollagen sponge in vitro, with significant proliferation noted on days 3 and 5 (Ohno et al., 2009) . The authors credited the cellular entry to the large pore size. BM MSCs labeled with a fluorochrome and seeded within a 1% hydrochloric acid atelocollagen gel were found to have "good proliferation" in vitro (Kanemaru et al., 2003) . Similarly, " a large number" of fluorochrome-labeled cells were observed in canine vocal folds eight weeks after having been injected with ASCs within an atelocollagen scaffold . Despite this, atelocollagen has the distinct disadvantage of being an animal derived substance, which brings with it the threat of immune response activation or transmission of an endogenous retrovirus. A third reported scaffold biomaterial for vocal fold stem cell applications is fibrin. Long et al. (2009 ) was able to demonstrate in vitro that a fibrin-based construct seeded with ASCs have good physical integrity and handling characteristics, slow degradation patterns and an ability to support cell viability. Recent findings demonstrate that these constructs have the elastic modulus and collagen orientation similar to native vocal mucosa, and are able to withstand oscillation when sutured onto an excised cadaveric larynx on top of pipe through which air can flow . See Native vocal fold cover of cadaveric larynx has been replaced with a tissue engineered construct and vibrated with air from an underlying pipe. Arrows mark the edges of the construct. The top of images is the anterior commissure. These images were captured with a high speed camera.
An optimal scaffold for stem cell applications for vocal fold regeneration would be noninflammatory, nonimmunogenic, encourage adherence and viability of resident cells, support appropriate cell-cell signaling, biodegrade at an acceptable rate, remain intact during investigator handling, as well as be able to sustain vocal fold vibration. The scaffold materials listed previously have demonstrated some of these attributes in animal models, but applications in conjunction with stem cell approaches is scant, currently. There exists a great opportunity to advance vocal fold regeneration strategies by finding an optimal scaffold to deliver cells and growth factors.
Growth factor delivery
To date, the delivery of only a few growth factors, including epidermal growth factor (EGF) fibroblast growth factor (FGF) and hepatocyte growth factor (HGF) have been investigated within MSC-based therapies for vocal fold regeneration. All of this work has been completed in vitro. The effect of soluble signaling has been used to examine the differentiation potential of ASCs. A bilayered, three dimensional construct was created in vitro by seeding ASCs within fibrin hydrogels, and once gelation was complete, additional ASCs were added directly on top. When EGF, FGF and retinoic acid were added to the media surrounding these constructs, it was found that EGF encouraged differentiation of ASCs into epithelial cells more efficiently than the other soluble signals (Long et al., 2009 ). The authors found that the cells on the top, epithelial-like surface stained positive for E-cadherin and cytokeratin 8, epithelial phenotype markers. It was found that these cells differentiated along this lineage only when they had an air interface and exposure to EGF. Interestingly, the authors hypothesized that mechanotransduction may have also played a role in differentiation, as the cells were cultured on a matrix with similar stiffness to the lamina propria. The cells on the inside of the hydrogel stained positive for vimentin, a cytoskeletal protein expressed by cells of mesenchymal origin. It should be noted that during the two week culture period, the epithelial cells did not form a confluent layer, suggestive of reduced efficiency of differentiation and proliferation of epithelial cells. HGF is known to have strong anti-fibrotic activity, and has been investigated in the voice literature as a stand-alone injection to remediate vocal fold scarring in an animal model (Hirano et al., 2004) . In this study, the HGF treated vocal folds had improved rheometric measurements and less collagen deposition than the scarred, untreated vocal folds. In the MSC literature, HGF has been implicated as being secreted by ASCs and encouraging an anti-fibrotic extracellular matrix profile when they are in co-culture with scar fibroblasts (Kumai, 2009) . Following vocal fold scarring, ASCs and scar fibroblasts (SF) were isolated from male ferrets, and then co-cultured in a variety of conditions to investigate their relationship with HGF. In order to demonstrate that HGF was one of the growth factors implicated in reducing the production of collagen, a neutralization assay was used. Following four days of co-culture of ASCs and SFs with an anti HGF antibody in the medium, the SFs had significantly higher amounts of collagen secretion than in the control condition. This condition did not affect HA secretion, and thus it was concluded that the HGF secreted by ASCs encourages the anti-fibrotic profile of SFs by downregulating collagen production, but not by upregulating HA production. Additionally, the authors suggested that a tissue engineering construct delivering HGF through ASCs to the vocal fold microenvironment rather than through an exogenous agent is preferable because of the slow release associated with having residency in the tissue and the potential activation of concurrent endogenous facilitatory factors. So, while there have been few studies of introducing growth factors exogenously to tissue engineering for vocal fold regeneration, endogenous growth factors are often thought to be present.
Future directions
Bioreactors
Bioreactors provide ex vivo mechanical stimulation that mimics a specific tissue's microenvironment for cells in media. With regard to laryngeal research, bioreactors can provide a unique model for studying the effects of vibration (similar to phonation) on cells in a controlled environment. For the custom designed bioreactors currently used in this line of research, frequency, amplitude and duration of vibration and tension of the substrate which cells are adherent to can often be programmed according to the experimental question of interest. There are many potential applications of this technology, including examination of the effects of dosage of vibration on cells of various laryngeal diseases, investigation of scar fibroblast activity at varying time intervals post laryngeal surgery (to inform recommendations about when to resume voicing post-operatively) and to compare the effects different laryngeal configurations during phonation on healing (to mimic different voice therapies at the cellular level), etc. While there have been several reports of the effects of stem cell therapies on ECM production, few studies have investigated the mechanisms for encouraging specific vocal fold ECM profiles. Bioreactors may provide a mode of inquiry toward these ends. Interestingly, recent literature suggests that fibroblasts are able to convert mechanical stimuli into ECM modifications, and thereby induce tissue remodeling via mechanotransduction (Ingber, 2006) . Recent voice research using bioreactors have found significant vibration induced changes in the ECM profile. For example, human dermal fibroblasts vibrated in hydrogels for periods of five and ten days demonstrated increased expression of HA synthase 2, decorin and fibromodulin (Kutty & Webb, 2010) . Human laryngeal fibroblasts vibrated for periods between 1-21 days showed an increased production of fibronectin and collagen type I (Wolchok et al., 2009) . Finally, human vocal fold fibroblasts vibrated for 6 hours showed an upregulation of fibronectin and HAassociated genes (Titze et al., 2004) . Comparison of the ECM produced by multiple cell types exposed to vibration that mimics phonation may help scientists determine an optimal cell source for vocal fold bioengineering. Currently bioreactors provide a research model, but in the future they may be utilized in therapeutic inventions. It may be found that cells can be primed in a bioreactor to create an optimal ECM profile before they are implanted into an organism with scarring or other vocal pathology. The use of bioreactors is a promising line of research that could shape future tissue regeneration approaches.
Conclusion
The regenerative potential of vocal fold tissue is a topic that is currently being investigated by an increasing number of teams internationally. While the literature to date has merely scratched the surface of the basic parameters involved in laryngeal tissue engineering, there is great opportunity for advancement of the knowledge base with the advent of high throughput experimental techniques, systems biology approaches and their associated statistical analysis. These developments allow for more efficient and comprehensive assessments of cell/scaffold interactions and ECM production profiles. Current themes in the literature include morphological and rheological outcomes of cell based therapies and how to use scaffolds and bioreactors to encourage optimal ECM regeneration. Future topics may include how to encourage efficient differentiation into epithelial cells via signaling mechanisms, how to engineer confluent and distinct layers that mimic normal vocal fold anatomy, how to induce angiogenesis that will be able to withstand vibration without hemorrhage and how to innervate the tissue.
